导管消融作为心房颤动一线治疗方案:进展与思考
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.75

基金项目:

上海市卫生健康委员会科研项目面上项目(202140497).


Catheter ablation as a first-line treatment strategy for atrial fibrillation: progress and thinking
Author:
Affiliation:

Fund Project:

Supported by General Program of Scientific Research Project of Shanghai Municipal Health Commission (202140497).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    心房颤动是临床上常见的心律失常,严重危害人类健康,早期有效控制心房颤动发作并减少并发症是其治疗重点。鉴于导管消融是有创治疗手段,既往指南均推荐导管消融作为心房颤动的二线治疗策略。近年来随着导管消融技术的进步和优化,导管消融有望取代抗心律失常药物成为心房颤动的一线治疗方案。本文系统介绍了导管消融作为心房颤动一线治疗方案的探索,并探讨了有望成为心房颤动一线治疗的一些新技术。

    Abstract:

    Atrial fibrillation is a common arrhythmia in clinic and seriously endangers human health. The focus of treatment is to effectively control the onset of atrial fibrillation and reduce complications on the early stage. Since catheter ablation is an invasive treatment, previous guidelines have recommended catheter ablation as a second-line treatment strategy. In recent years, with the progress and optimization of catheter ablation technology, catheter ablation is expected to replace antiarrhythmic drugs as the first-line treatment of atrial fibrillation. This paper systematically introduces the exploration of catheter ablation as the first-line treatment of atrial fibrillation, and discusses some new technologies that are expected to become the first-line treatment of atrial fibrillation.

    参考文献
    相似文献
    引证文献
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2022-03-01
  • 最后修改日期:2022-03-30
  • 录用日期:
  • 在线发布日期: 2022-05-25
  • 出版日期:
文章二维码
重要通知
友情提醒: 近日发现论文正式见刊或网络首发后,有人冒充我刊编辑部名义给作者发邮件,要求添加微信,此系诈骗行为!可致电编辑部核实:021-81870792。
            《海军军医大学学报》编辑部
关闭